Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

129 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Type does matter. Use VIRGIN olive oil as your preferred fat to reduce your risk of breast cancer: case-control EpiGEICAM study.
Donat-Vargas C, Guerrero-Zotano Á, Lope V, Bermejo B, Casas A, Baena-Cañada JM, Antolín S, Sánchez-Rovira P, Antón A, Garcia-Saénz JÁ, Ramos M, Muñoz M, de Juan A, Jara Sánchez C, Chacón JI, Gil-Gil M, Andrés Conejero R, Llombart A, Bezares S, Fernández de Larrea-Baz N, Pérez-Gómez B, Martín M, Pollán M. Donat-Vargas C, et al. Among authors: llombart a. Eur J Clin Nutr. 2022 Sep;76(9):1343-1346. doi: 10.1038/s41430-022-01101-w. Epub 2022 Feb 22. Eur J Clin Nutr. 2022. PMID: 35194197
Neoadjuvant endocrine therapy for breast cancer: past, present and future.
Barnadas A, Gil M, Sánchez-Rovira P, Llombart A, Adrover E, Estevez LG, de la Haba J, Calvo L. Barnadas A, et al. Among authors: llombart a. Anticancer Drugs. 2008 Apr;19(4):339-47. doi: 10.1097/CAD.0b013e3282f97f75. Anticancer Drugs. 2008. PMID: 18454044 Review.
Lower Breast Cancer Risk among Women following the World Cancer Research Fund and American Institute for Cancer Research Lifestyle Recommendations: EpiGEICAM Case-Control Study.
Castelló A, Martín M, Ruiz A, Casas AM, Baena-Cañada JM, Lope V, Antolín S, Sánchez P, Ramos M, Antón A, Muñoz M, Bermejo B, De Juan-Ferré A, Jara C, Chacón JI, Jimeno MA, Rosado P, Díaz E, Guillem V, Lluch A, Carrasco E, Pérez-Gómez B, Vioque J, Pollán M; EpiGEICAM Researchers. Castelló A, et al. PLoS One. 2015 May 15;10(5):e0126096. doi: 10.1371/journal.pone.0126096. eCollection 2015. PLoS One. 2015. PMID: 25978407 Free PMC article.
Nab-Paclitaxel in Metastatic Breast Cancer: Defining the Best Patient Profile.
González-Martín A, Alba E, Ciruelos E, Cortés J, Llombart A, Lluch A, Andrés R, Álvarez I, Aramendía JM, de la Peña FA, Barnadas A, Batista N, Calvo L, Galve E, García-Palomo A, García-Sáenz JÁ, de la Haba J, López R, López-Vivanco G, Martínez-Jáñez N, de Dueñas EM, Plazaola A, Rodríguez-Lescure Á, Ruiz M, Sánchez-Rovira P, Santaballa A, Seguí MÁ, Tusquets I, Zamora P, Martín M. González-Martín A, et al. Among authors: llombart a. Curr Cancer Drug Targets. 2016;16(5):415-28. doi: 10.2174/1568009615666150817121731. Curr Cancer Drug Targets. 2016. PMID: 26278712 Review.
Equity, barriers and cancer disparities: study of the Spanish Society of Medical Oncology on the access to oncologic drugs in the Spanish Regions.
Salvador J, Aparicio J, Baron FJ, Garcia-Campelo R, Garcia-Carbonero R, Lianes P, Llombart A, Isla D, Piera JM, Munoz M, Puente J, Rivera F, Rodriguez CA, Virizuela JA, Martin M, Garrido P. Salvador J, et al. Among authors: llombart a. Clin Transl Oncol. 2017 Mar;19(3):341-356. doi: 10.1007/s12094-016-1535-8. Epub 2016 Aug 25. Clin Transl Oncol. 2017. PMID: 27562312 Free PMC article.
Frequency of breast cancer with hereditary risk features in Spain: Analysis from GEICAM "El Álamo III" retrospective study.
Márquez-Rodas I, Pollán M, Escudero MJ, Ruiz A, Martín M, Santaballa A, Martínez Del Prado P, Batista N, Andrés R, Antón A, Llombart A, Fernandez Aramburu A, Adrover E, González S, Seguí MA, Calvo L, Lizón J, Rodríguez Lescure Á, Ramón Y Cajal T, Llort G, Jara C, Carrasco E, López-Tarruella S. Márquez-Rodas I, et al. Among authors: llombart a. PLoS One. 2017 Oct 6;12(10):e0184181. doi: 10.1371/journal.pone.0184181. eCollection 2017. PLoS One. 2017. PMID: 28985233 Free PMC article.
Phase III Trial of Adjuvant Capecitabine After Standard Neo-/Adjuvant Chemotherapy in Patients With Early Triple-Negative Breast Cancer (GEICAM/2003-11_CIBOMA/2004-01).
Lluch A, Barrios CH, Torrecillas L, Ruiz-Borrego M, Bines J, Segalla J, Guerrero-Zotano Á, García-Sáenz JA, Torres R, de la Haba J, García-Martínez E, Gómez HL, Llombart A, Bofill JS, Baena-Cañada JM, Barnadas A, Calvo L, Pérez-Michel L, Ramos M, Fernández I, Rodríguez-Lescure Á, Cárdenas J, Vinholes J, Martínez de Dueñas E, Godes MJ, Seguí MA, Antón A, López-Álvarez P, Moncayo J, Amorim G, Villar E, Reyes S, Sampaio C, Cardemil B, Escudero MJ, Bezares S, Carrasco E, Martín M; GEICAM Spanish Breast Cancer Group; CIBOMA (Iberoamerican Coalition for Research in Breast Oncology); LACOG (Latin American Cooperative Oncology Group). Lluch A, et al. Among authors: llombart a. J Clin Oncol. 2020 Jan 20;38(3):203-213. doi: 10.1200/JCO.19.00904. Epub 2019 Dec 5. J Clin Oncol. 2020. PMID: 31804894 Free PMC article. Clinical Trial.
129 results